Leading with Experience

At Worldwide Clinical Trials you benefit from outstanding expertise in the field of cardiovascular research. Our global cardiovascular team combines experience in the practice of cardiology, advanced scientific research with a variety of novel chemical entities and, more than 20 years of running complex global cardiovascular clinical studies, in the effective management of your trial.  Our expertise and reputation for throughput with data of impeccable quality allow us to maintain close relationships with key opinion leaders and practitioners in the field, which translates into superior results and consistently predictable recruitment rates for your study.

Phase I-IV Experience:

  • Coronary Artery Disease, including Acute Coronary Syndrome
  • Arterial Hypertension
  • Heart Failure/Left Ventricular Dysfunction
  • Peripheral Vascular Disease


Expertise on Any Scale - Large Outcomes Trials

By definition, cardiovascular outcomes studies enroll thousands of patients across hundreds of centers worldwide with outcomes that can materially affect standards of care. Centers are representative of the practicing community in various geographic regions, patient eligibility criteria is often highly inclusive, and outcome measures unambiguously medically significant (e.g. all-cause mortality, cardiac death, and major cardiovascular disability).

The nature of these trials places a premium on scalable infrastructure that is fully adaptable for randomization, specifically;

-    flexible data management services
-    experienced clinical drug supply management
-    highly coordinated clinical trial management services and
-    an ability to manage data flow and reporting for event adjudication purposes. 

We deliver you this operational acumen, along with team composition and communication strategies coordinating multiple centres and vendors, and ultimately, the ability to meet milestones and timelines.

Setting the Industry Standard

The results of some of our most notable cardiovascular studies include references to our unique capabilities and have been published in peer reviewed journals including; the Journal of the American Medical Association (JAMA), The Lancet, Journal of the American College of Cardiology (JACC), The New England Journal of Medicine (NEJM), Circulation and The European Heart Journal.  Examples are listed below:

  • MERLIN – TIMI 36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes)
  • PROVE IT – TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy)
  • PROACTIVE (PROspective pioglitazone Clinical Trial in Macrovascular Events)
  • EMIP-FR (European Myocardial Infarction Project - Free Radicals)
  • HERO-2  (Hirulog in Early Reperfusion/Occlusion 2)
  • MAGIC (Magnesium in Acute Coronary Syndromes)
  • CARISA (Combination Assessment of Ranolazine in Stable Angina)
  • ERICA (Evaluation of Ranolazine in Chronic Angina)